Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIR 19 in Moderate COVID-19
NCT05184127Phase 2Completed
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Peptides, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Mir-19 in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Relief of fever at 14 days, Respiratory rate at 14 days and 2 more. Started Apr 2021; status: completed.
02
Drugs
Mir-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05184127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184127.